ImmunityBio, Inc. (IBRX) Stock Grade

About ImmunityBio, Inc.'s fundamentals

ImmunityBio is a biotechnology company with a market capitalization of $1.8 billion that has demonstrated exceptional revenue growth of 668.3% year-over-year, indicating rapidly expanding commercial activity or milestone achievements. However, the company is currently unprofitable with a net margin of -310.2% and reported a net loss in its latest annual statement, meaning expenses significantly exceed revenues. The unusually high return on equity of 70.3% reflects the company's negative earnings base rather than operational efficiency, which is common in early-stage biotech firms still in development phases. ImmunityBio does not pay a dividend and lacks a meaningful P/E ratio due to its net loss position.